Association of FGF-2 Concentrations with Atheroma Progression in Chronic Kidney Disease Patients
Bozić Stanojević, Milica
MetadataShow full item record
Background and objectives: Atherosclerosis is highly prevalent in CKD. The rate of progression of atherosclerosis is associated with cardiovascular events. Fibroblast growth factor 2 (FGF-2) is a member of the FGF family with potentially both protective and deleterious effects in the development of
atherosclerosis. The role of circulating FGF-2 levels in the progression of atherosclerosis in CKD is unknown. Design, setting, participants, & measurements: We used a multicenter, prospective, observational cohorts study of 481 patients with CKD. We determined the presence of atheroma plaque in ten arterial territories by carotid and femoral ultrasounds. Progression of atheromatosis was defined as an increase in the number of territories with plaque after 24 months. Plasma levels of FGF-2 were measured by multiplex analysis. A multivariable logistic regression analysis was performed to determine whether plasma FGF-2 levels were associated with atheromatosis progression. Results: Average age of the population was 61 years. The percentage of patients in each CKD stage was 51% in stage 3, 41% in stages 4–5, and 8% in dialysis. A total of 335 patients (70%) showed plaque at baseline. Atheromatosis progressed in 289 patients (67%). FGF-2 levels were similar between patients with or without plaque at baseline (79 versus 88 pg/ml), but lower in patients with atheromatosis progression after 2 years (78 versus 98 pg/ml; P<0.01). In adjusted analyses, higher plasma FGF-2 was associated with lower risk of atheromatosis progression (odds ratio [OR], 0.86; 95% confidence interval [95% CI], 0.76 to 0.96; per 50 pg/ml increment). Analysis of FGF-2 in tertiles showed that atheroma progression was observed for 102 participants in the lowest tertile of FGF-2 (reference group), 86 participants in the middle tertile of FGF-2 (adjusted OR, 0.70; 95% CI, 0.40 to 1.20), and 74 participants in the lowest tertile of FGF-2 (adjusted OR, 0.48; 95% CI, 0.28 to 0.82). Conclusions: Low FGF-2 levels are independently associated with atheromatosis progression in CKD.
Is part ofClinical Journal of The American Society of Nephrology, 2018, vol. 13, núm. 4, p. 577-584
Showing items related by title, author, creator and subject.
Association of Candidate Gene Polymorphisms With Chronic Kidney Disease: Results of a Case-Control Analysis in the Nefrona Cohort Valls, Joan; Cambray Carner, Serafí; Pérez-Guallar, Carles; Bozić Stanojević, Milica; Bermúdez López, Marcelino; Fernández i Giráldez, Elvira; Betriu i Bars, M. Àngels; Rodríguez, Isabel; Valdivielso Revilla, José Manuel (Frontiers Media, 2019)Chronic kidney disease (CKD) is a major risk factor for end-stage renal disease, cardiovascular disease and premature death. Despite classical clinical risk factors for CKD and some genetic risk factors have been identified, ...
Factors predicting cardiovascular events in chronic kidney disease patients. Role of subclinical atheromatosis extent assessed by vascular ultrasound Valdivielso Revilla, José Manuel; Betriu i Bars, M. Àngels; Martínez Alonso, Montserrat; Arroyo, David; Bermúdez López, Marcelino; Fernández i Giráldez, Elvira (Public Library of Science, 2017)Patients with chronic kidney disease (CKD) have an increased incidence of cardiovascular events (CVE). The contribution of subclinical atheromatosis extent, including femoral arteries, to CVE in CKD patients has not been ...
Combination of biomarkers of vascular calcification and sTWEAK to predict cardiovascular events in chronic kidney disease. Bozić Stanojević, Milica; Méndez-Barbero, Nerea; Gutiérrez-Muñoz, Carmen; Betriu i Bars, M. Àngels; Egido, Jesús; Fernández i Giráldez, Elvira; Martín-Ventura, JL.; Valdivielso Revilla, José Manuel; Blanco-Colio, LM. (Elsevier, 2018)BACKGROUND AND AIMS: Vascular calcification (VC) and atherosclerosis are associated with an increased cardiovascular morbimortality in chronic kidney disease (CKD). Osteoprotegerin (OPG) and osteopontin (OPN) are involved ...